热门资讯> 正文

生物GAAP每股收益攀升-0.13美元

2025-08-12 23:51

Climb Bio press release (NASDAQ:CLYM): Q2 GAAP EPS of -$0.13.
Cash, cash equivalents and marketable securities were $187.4 million as of June 30.
Cash, cash equivalents and marketable securities are expected to fund operations through 2027.
Other income, net was $2.0 million for the three months ended June 30, 2025, compared to $1.5 for the comparable period in 2024.

More on Climb Bio

Climb Bio appoints Edgar D. Charles as Chief Medical Officer
Seeking Alpha’s Quant Rating on Climb Bio
Historical earnings data for Climb Bio
Financial information for Climb Bio

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。